This phase II trial studies how well erdafitinib in combination with abiraterone acetate or
enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Testosterone can cause the growth of prostate cancer cells. Abiraterone acetate lowers the
amount of testosterone made by the body. This may help stop the growth of tumor cells that
need testosterone to grow. Enzalutamide blocks the use of testosterone by the tumor cells.
Giving erdafitinib with abiraterone acetate or enzalutamide may work better in treating
patients with prostate cancer compared to abiraterone acetate or enzalutamide alone.
OUTLINE: Patients receive abiraterone acetate orally (PO) once daily (QD) or enzalutamide PO
QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21
days for 2 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.